CoChat

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

Open access
Kadowaki, Takashi, Chin, Rina, Ozeki, Akichika, Imaoka, Takeshi, Ogawa, Yoshihiro · 2022 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

Background Due to potential ethnic differences in the pathophysiology of type 2 diabetes, new therapeutics need to be evaluated in Japanese patients. We aimed to assess the safety and glycaemic efficacy of tirzepatide as an add-on treatment in Japanese patients with type 2 diabetes who had inadequate glycaemic control with stable doses of various oral antihyperglycaemic monotherapies. Methods This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan. Eligible participants were aged 20 years or older with inadequately controlled (HbA 1c ≥7·0% to 2 or higher, and stable bodyweight (±5%) for at least 3 months before screening. After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interactive web response system, stratified by oral antihyperglycaemic medication group. All participants started receiving 2·5 mg tirzepatide and doses were escalated by 2·5 mg every 4 weeks until the assigned dose was reached. The primary endpoint was safety and tolerability during 52 weeks of treatment, assessed as incidence of treatment-emergent adverse events in the modified intention-to-treat (mITT) population. This trial is registered with ClinicalTrials.gov, NCT03861039. Findings Be…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00187-5

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. 2021, Introduction: standards of medical care in diabetes-2021, Diabetes Care, 44, S1

Cited by

See all 144

Metadata

Authors
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y.
Affiliations
  • Toranomon Hospital (JP)
  • Eli Lilly (Japan) (JP)
  • Kyushu University (JP)
Corresponding author
Chin, Rina
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2022-09
Volume
10
Issue
9
Pages
634-644
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4288735703
Cited by
131
References
31
Citations by year
2026: 19 · 2025: 38 · 2024: 33 · 2023: 31 · 2022: 10
FWCI
20.74
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (acceptedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, type 2 diabetes, adjunctive therapy, glycemic control, HbA1c, safety and tolerability, Japanese patients, GIP/GLP-1 receptor agonist, sulfonylureas, biguanides, SGLT2 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, glinides, adverse events, dose escalation
MeSH terms
Tirzepatide, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Japan, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00187-5
The paper
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022). Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00187-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.